What is the recommended dose of polymyxin (polymyxin B or polymyxin E (colistin)) for a general adult patient with normal renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 21, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Polymyxin Dosing in Adults with Normal Renal Function

Polymyxin B: Preferred Agent

For adults with normal renal function, administer polymyxin B at 2.5-3.0 mg/kg/day divided into 2 daily intravenous doses, preceded by a mandatory loading dose of 2-2.5 mg/kg. 1

Standard Dosing Protocol

  • Loading dose: 2-2.5 mg/kg administered as the first dose to rapidly achieve therapeutic plasma concentrations 2, 1
  • Maintenance dose: 1.5-3 mg/kg/day (typically 2.5-3.0 mg/kg/day) divided into 2 daily doses 2, 1
  • Critical advantage: No dose adjustment required for renal impairment, as polymyxin B clearance is not influenced by renal function 3, 4

Key Pharmacokinetic Considerations

  • Polymyxin B is administered as the active drug (not a prodrug), allowing immediate therapeutic effect 2
  • Total body clearance shows remarkably low interindividual variability (32.4% coefficient of variation) when scaled by total body weight 4
  • Dosing should be based on actual body weight, not ideal body weight 5, 4
  • The drug is predominantly non-renally cleared with median urinary recovery of only 4.04% 4

Colistin (Colistimethate Sodium): Alternative Agent

If polymyxin B is unavailable, administer colistin with a loading dose of 6-9 million IU regardless of renal function, followed by maintenance doses of 4.5 million IU every 12 hours in patients with normal renal function. 2, 6

Standard Dosing Protocol

  • Loading dose: 6-9 million IU (critical for all patients regardless of renal function) 2, 6
  • Maintenance dose: 4.5 million IU every 12 hours for critically ill patients with creatinine clearance >50 mL/min 2, 6
  • Alternative maintenance: 2.5-5 mg/kg/day divided into 2-4 doses, or 9 million IU/day in 2-3 divided doses 6, 7

Important Pharmacokinetic Differences

  • Colistin is administered as colistimethate sodium (CMS), an inactive prodrug that requires conversion to active colistin 6
  • One million IU of colistin equals 80 mg of colistimethate sodium 3, 6
  • Plasma colistin concentrations remain sub-optimal for 2-3 days before reaching steady state without a loading dose 2
  • The loading dose is critical because colistin displays a relatively long half-life in relation to dosing intervals 2, 6

Critical Clinical Pitfalls to Avoid

Never Omit the Loading Dose

  • Failure to administer a loading dose results in subtherapeutic levels for the first 24-48 hours, regardless of which polymyxin is used 2, 1
  • This delay in achieving therapeutic concentrations can lead to clinical failure and increased mortality 3

Do Not Confuse Polymyxin B with Colistin Dosing

  • These agents have completely different unit conversions and dosing requirements 1
  • Polymyxin B is dosed in mg/kg, while colistin is dosed in million IU 2, 1

Avoid Monotherapy When Possible

  • Polymyxin B should be used in combination therapy rather than monotherapy for carbapenem-resistant infections 1
  • For ventilator-associated pneumonia with suspected multidrug-resistant gram-negative pathogens, combine with an antipseudomonal β-lactam agent 1

Minimize Concurrent Nephrotoxic Agents

  • Avoid concurrent use of aminoglycosides, NSAIDs, diuretics, and ACE inhibitors/ARBs to minimize nephrotoxicity risk 1
  • Concurrent vancomycin use increases nephrotoxicity risk (HR 1.89) 8
  • Contrast media administration increases nephrotoxicity risk (HR 1.79) 8

Nephrotoxicity Considerations

Polymyxin B Has Lower Nephrotoxicity

  • Polymyxin B causes nephrotoxicity in 11.8% of patients versus 39.3% with colistin 3, 1
  • The incidence of renal failure is significantly lower with polymyxin B than colistin 2, 3

Risk Factors for Nephrotoxicity

  • Higher daily doses by actual body weight increase nephrotoxicity risk (HR 1.73 per mg/kg increase) 8
  • Median onset of nephrotoxicity occurs at 9 days of therapy 8
  • Most nephrotoxicity is reversible within one week after discontinuation 3

Monitoring Requirements

  • Monitor renal function closely at baseline and 2-3 times per week during treatment 6
  • Acute kidney injury during treatment is a major factor related to clinical failure and mortality 3, 6

Special Administration Considerations

Infusion Method for Colistin

  • A 4-hour infusion is suggested to optimize pharmacokinetic/pharmacodynamic properties 6
  • For intravenous administration, slowly inject one-half of the total daily dose over 3-5 minutes every 12 hours 7

Therapeutic Drug Monitoring for Polymyxin B

  • Target steady-state average concentration of approximately 3.35 mg/L 1
  • Optimal AUCss,24h target is 50-100 mg·h/L 1

References

Guideline

Polymyxin B Dosing and Administration in Critical Care

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Polymyxin B in Renal Impairment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013

Guideline

Colistin Dosage Administration in Patients with Impaired Renal Function

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Risk factors for nephrotoxicity onset associated with polymyxin B therapy.

The Journal of antimicrobial chemotherapy, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.